SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is surging significantly after reporting that a Phase 3 trial for its personalized mRNA cancer vaccine, developed in combination with Merck, met its primary endpoints in treating high-risk melanoma. The move has triggered intense activity from both retail and institutional investors, fueling a major short squeeze and renewed optimism across the broader biotech sector regarding mRNA-based oncology applications.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Marvell Technology is trending after announcing a landmark multi-year partnership with Alphabet to develop custom AI silicon for the TPU ecosystem, including a significant $12.2 billion warrant agreement. The community is actively debating the stock's valuation, weighing the long-term revenue potential of this custom chip collaboration against concerns regarding potential share dilution and competitive positioning against rival semiconductor giants.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is facing downward pressure amid investor profit-taking and concerns regarding the long-term financial risks of its off-balance-sheet AI financing vehicles. Despite these headwinds, the community remains divided, with many bulls viewing the current pullback as a prime buying opportunity ahead of upcoming earnings, while others remain skeptical of the stock's recent volatility and valuation.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Sellas Life Sciences is trending as investors digest major industry validation for cancer vaccines, fueling community optimism for a potential acquisition and an imminent phase 3 data readout. The discussion is dominated by bullish sentiment regarding the GPS platform's competitive advantage in oncology, while some participants debate trial modeling and the potential for a massive valuation re-rating.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

Merck is trending as investor focus intensifies on potential oncology acquisitions to bolster its pipeline and mitigate the long-term impact of upcoming patent expirations. The community is actively debating the likelihood of a buyout for emerging biotech firms, with a strong focus on which companies could provide a strategic platform to extend Merck's market leadership in cancer therapeutics.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

Market participants are fixated on treasury liquidity support and FOMC minutes, driving intense debate over whether recent volatility signals a systemic warning or a standard consolidation. The community remains deeply divided between those betting on continued AI-led momentum and bears who cite macro headwinds like rising yields and escalating geopolitical tensions as catalysts for a deeper pullback.

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.

Tempus AI Inc. - Ordinary Shares - Class A

Tempus AI Inc

Tempus AI is experiencing significant market interest driven by its role as an AI-powered healthcare leader, with strong community discussion focusing on its massive short interest and potential as a short-squeeze candidate. The conversation is currently fueled by a combination of institutional positioning, including notable backing by major tech players, and ongoing enthusiasm for its precision medicine and clinical oncology data platform.

WhiteFiber, Inc. provides AI and HPC infrastructure & cloud and data center solutions. It operates through the following segments: Cloud Services and Colocation Services. The Cloud Services segment offers computing services to support generative AI workstreams. The Colocation Services segment provides customers with physical space, power and cooling within the data center facility. The company was founded on August 15, 2024 and is headquartered in New York, NY.

Whitefiber Inc.

WhiteFiber, Inc.

WhiteFiber is trending due to investor reaction to the company's upsized $270M convertible senior notes offering due 2032, which has sparked intense debate over potential equity dilution versus long-term growth potential for its data center expansion. The community remains deeply divided, with some investors viewing the price drop as a generational buying opportunity to accumulate shares for a rebound, while others express concerns over management's capital allocation and the impact of the financing on current valuation.

SPDR Series Trust - State Street SPDR S&P Biotech ETF

SPDR S&P Biotech ETF

The SPDR S&P Biotech ETF (XBI) is trending as the sector experiences significant momentum, largely driven by positive phase 3 clinical results for oncology and vaccine programs that have ignited M&A speculation and investor enthusiasm. Community discussion is heavily focused on the potential for a biotech bull run, with active debates centered on the high short interest in specific names, the impact of recent oncology breakthroughs on the broader sector, and positioning ahead of anticipated Q3 earnings.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

The stock is trending as market participants weigh Treasury's decision to expand debt buyback operations against broader anxieties regarding high yields, escalating Middle East geopolitical risks, and sustainability concerns surrounding AI infrastructure spending. Community sentiment remains deeply polarized, with many traders debating whether recent liquidity interventions provide a genuine relief catalyst or merely a temporary band-aid on underlying fiscal and debt-related vulnerabilities.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$NLST Of course, it would be wonderful if the CAFC disagrees with the PTAB’s FWDs on the ’060 and ’160 HBM patents, sending Micron back to Gilstrap in EDTX for the final step on damages for several past years. 
 
But even independently of that, termination of the ’087 PGR  opens the money flow from HBM anyway. With the PGR/IPR window now closed, Micron and SKH will ultimately have to account for ’087. Micron can continue fighting ’087 (and ’731) in Delaware, but without PTAB leverage, its invalidity challenge becomes considerably harder: in district court, invalidity must be proven by clear and convincing evidence, rather than the PTAB’s lower preponderance-of-the-evidence standard. 
 
I expect Micron to settle—not only because of the ITC investigation, but also for the hopeless case in WDTX (3 valid, final patents!) to avoid fighting ’087 and ’731 in district court without the PTAB leverage Samsung petitions  previously provided. 
 
Micron, throw in the towel! The bill only growing.

George

Robert Cobb

filippo

stephen white

H Kim

Jiri Treger

Jwows

Margaret Dorfman

ming yu

nicky balboa

Megabux

Jeffrey Jacobs

Paul

Rezaul hashem

Bill Rassbach

Reeltime

Robert Hunter

Kamran Mirza

Armin Schnabel

i 001

Greg Dodd

Rick B.

Gobbaghoull

ratatouille420

Jason DeBold

Average Joe

Bruno Ferdinand

Highest High

StockTwits For Android 

StockTwits Web

Netlist Inc

 Of course, it would be wonderful if the CAFC disagrees with the PTAB’s FWDs on the ’060 and ’160 HBM patents, sending Micron back to Gilstrap in EDTX for the final step on damages for several past years. 
 
But even independently of that, termination of the ’087 PGR  opens the money flow from HBM anyway. With the PGR/IPR window now closed, Micron and SKH will ultimately have to account for ’087. Micron can continue fighting ’087 (and ’731) in Delaware, but without PTAB leverage, its invalidity challenge becomes considerably harder: in district court, invalidity must be proven by clear and convincing evidence, rather than the PTAB’s lower preponderance-of-the-evidence standard. 
 
I expect Micron to settle—not only because of the ITC investigation, but also for the hopeless case in WDTX (3 valid, final patents!) to avoid fighting ’087 and ’731 in district court without the PTAB leverage Samsung petitions  previously provided. 
 
Micron, throw in the towel! The bill only growing.